RxDoctor Payments Data

Nicole Sellers, NP

Adult Health · Norfolk, VANPI 1629359237

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $8,250 of the $11,805 with a category attached, or 69.9%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 76.5% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $5,443 and has fallen 81.3% since, to $1,020 in 2025. Among adult health clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,805in general payments, 2019–2025

Across 47 payments — averaging $251.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$9K
  • Abbott$2K
  • AstraZeneca$238
  • Abiomed$147
  • Pfizer$143
  • Novo Nordisk$137
  • plus $223 from 3 others

What the payments were for

  • Speaking & faculty fees$8,25070%
  • Travel & lodging$1,13310%
  • Food & beverage$2,40820%
  • Education$140%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,805 in reported general payments places this provider in the 95th percentile of 368 adult health providers in Virginia.

See all adult health providers in Virginia

Medicare billing

Part B allowed, 2024
$1,330
Medicare patients
18
Services billed
18

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan27$30,435
FarxigaDapagliflozin Propanediol26$23,391
Repatha SureclickEvolocumab11$7,742
Potassium Chloride29$915
Bumetanide30$641
Metoprolol Succinate62$562
Spironolactone44$309
Carvedilol37$246
Losartan Potassium14$111
Hydralazine Hcl15$87
Amlodipine Besylate23$84
Furosemide16$78
Metolazone12$55

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$238$23,39126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 368 adult health providers in Virginia.

Other adult health in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →